Moderna Lifts 2026 Revenue Outlook to 25% Growth, Stock Jumps 10%
Moderna lifted its revenue outlook to 15%-25% growth after Q3 revenue of $1.3 billion beat estimates, and said it is preparing to file its cancer vaccine with regulators.
Topic
Mrna Vaccines
Topic
Mrna Vaccines
Moderna Posts 38-Cent Profit, Beats Estimates and Lifts 2026 Outlook
Moderna beat estimates with $1.31 billion in Q3 revenue and a 38-cent profit, raising 2026 growth guidance to 15-25% as new vacci…